4D Molecular Therapeutics, Inc.
General ticker "FDMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $312.1M (TTM average)
4D Molecular Therapeutics, Inc. follows the US Stock Market performance with the rate: 53.5%.
Estimated limits based on current volatility of 4.0%: low 10.26$, high 11.12$
Factors to consider:
- Total employees count: 227 (+54.4%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Limited operating history and no commercial products, High R&D costs, Regulatory and compliance, Need for additional capital, Rapid industry changes
- Current price 17.4% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.90$, 9.53$]
- 2025-12-31 to 2026-12-31 estimated range: [2.40$, 7.35$]
Financial Metrics affecting the FDMT estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -43.20 <= 0.33
- Positive: Shareholder equity ratio, % of 91.12 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
Short-term FDMT quotes
Long-term FDMT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.13MM | $20.72MM | $0.04MM |
| Operating Expenses | $113.16MM | $133.59MM | $187.88MM |
| Operating Income | $-110.03MM | $-112.87MM | $-187.84MM |
| Non-Operating Income | $2.54MM | $12.03MM | $26.97MM |
| R&D Expense | $80.25MM | $97.10MM | $141.30MM |
| Income(Loss) | $-107.49MM | $-100.84MM | $-160.87MM |
| Profit(Loss)* | $-107.49MM | $-100.84MM | $-160.87MM |
| Stockholders Equity | $231.34MM | $307.83MM | $510.61MM |
| Assets | $261.85MM | $339.89MM | $560.38MM |
| Operating Cash Flow | $-86.69MM | $-75.79MM | $-134.59MM |
| Capital expenditure | $11.54MM | $2.77MM | $3.79MM |
| Investing Cash Flow | $-17.05MM | $115.72MM | $-302.44MM |
| Financing Cash Flow | $3.08MM | $156.83MM | $337.25MM |
| Earnings Per Share** | $-3.32 | $-2.58 | $-2.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.